MAPK3 and Alzheimer disease: To gain more insight whether the increase in CSF-ERK1/2 in AD represents simply another marker of neuronal destruction in addition to Tau, or if possibly different cell populations or distinct underlying molecular mechanisms are reflected, it might be interesting to measure CSF-ERK1/2 levels in patients with other non-AD neurodegenerative disorders.